For the first time, the anti-steatotic action of an amphibian skin peptide, namely macrotympanain A1 (MA1- FLPGLECVW), has been demonstrated in a well-established in vitro model of hepatic steatosis. This evidence concerns the gene PNMA1 and fatty liver disease.